SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1479)4/20/2003 9:41:26 PM
From: quidditch   of 3044
 
"The FDA cannot really say no unless there are some undisclosed and very negative side-effects."

And, just to review the bidding, what are the potential markets for MM and solid tumors, the latter being the large pot in the center of the table? $250-$300m for MM if adopted as a standard treatment.

And, I know I asked this several months ago, in terms of method of action, what does the board think the differences are in bio-chemical determinants between MM and solid tumors? Is it likely to be differences in cancer cell sites, depending on whether its CC, hepatic or LC,
or an entirely different method of action to suppress bad cell formation/promote cell death? Do Levin and crew have a clue if these are in the same ball park or a shot in the dark? I'm aware that this is reducing the discussion to the LCD, but it will help me catch on toa conceptual approach.

quid
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News